Combination therapy doubles survival in mice with mesothelioma

21 May 2018 by under Research/Treatment

research test tubes 100x100 Combination therapy doubles survival in mice with mesotheliomaCombining two cancer immunotherapy drugs – a novel immune modulator and a therapy that activates the anti-tumor immune response – more than doubled survival in laboratory mice with malignant mesothelioma, according to a report published in Cancer Immunology Research.

Researches from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) added AMD3100 (plerixafo), a treatment approved to stimulate stem cell production prior to bone marrow transplantation, to the investigational drug VIC-008, significantly improving survival in the mice.

is a rare but aggressive form of cancer that affects the lining of the lungs or other organs. It is caused by exposure to , a fibrous mineral that was commonly used in building material and other industry products.

Mesothelioma usually proves deadly within 12 to 18 months after diagnosis. “Since the advent of cancer immunotherapy, people have tried to apply immunotherapeutic drugs to mesothelioma with limited success,” said Mark Poznansky, MD, PhD, director of the MGH-VIC and senior author of the report. “We are very excited at the prospect that this drug combination may be much more effective in prolonging patients’ lives.”

VIC-008 is a fusion protein that combines an immune-activating protein from the tuberculosis bacteria with a small antibody fragment targeting mesothelin, a protein expressed in several types of tumor, including mesothelioma, pancreatic and ovarian cancer. Pevious studies have shown this molecule to be effective in a mouse model of ovarian cancer.

Source: News Medical Life Sciences

Comments are closed.